177 related articles for article (PubMed ID: 15476849)
1. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
Singh RP; Agarwal R
Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer chemoprevention by silibinin: bench to bedside.
Singh RP; Agarwal R
Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
[TBL] [Abstract][Full Text] [Related]
3. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer prevention by silibinin.
Singh RP; Agarwal R
Curr Cancer Drug Targets; 2004 Feb; 4(1):1-11. PubMed ID: 14965263
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of novel agents for prostate cancer chemoprevention.
Singh RP; Agarwal R
Endocr Relat Cancer; 2006 Sep; 13(3):751-78. PubMed ID: 16954429
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive efficacy of silymarin in skin and prostate cancer.
Deep G; Agarwal R
Integr Cancer Ther; 2007 Jun; 6(2):130-45. PubMed ID: 17548792
[TBL] [Abstract][Full Text] [Related]
8. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
9. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
11. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
[TBL] [Abstract][Full Text] [Related]
12. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer.
Singh RP; Agarwal R
Eur J Cancer; 2005 Sep; 41(13):1969-79. PubMed ID: 16084079
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer and inositol hexaphosphate: efficacy and mechanisms.
Singh RP; Agarwal R
Anticancer Res; 2005; 25(4):2891-903. PubMed ID: 16080543
[TBL] [Abstract][Full Text] [Related]
15. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
[TBL] [Abstract][Full Text] [Related]
16. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
17. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels.
Verschoyle RD; Greaves P; Patel K; Marsden DA; Brown K; Steward WP; Gescher AJ
Eur J Cancer; 2008 Apr; 44(6):898-906. PubMed ID: 18343654
[TBL] [Abstract][Full Text] [Related]
19. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
20. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
